Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UGCG | Q16739 | 10/20 | 0.98 |
| ▸ | MEN1 | O00255 | 2/20 | 0.80 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.80 |
| ▸ | TP53 | P04637 | 1/20 | 0.80 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.80 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.80 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.80 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.80 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.80 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.80 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.80 |
| ▸ | MAPT | P10636 | 1/20 | 0.80 |
| ▸ | MTOR | P42345 | 1/20 | 0.80 |
| ▸ | GMNN | O75496 | 1/20 | 0.79 |
| ▸ | LMNA | P02545 | 1/20 | 0.79 |
| ▸ | BLM | P54132 | 1/20 | 0.79 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.79 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.79 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.79 |
| ▸ | HTR1A | P08908 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7797129 | 1.00 | UGCG (0.98) | UGCGMEN1KMT2ATP53CYP3A4 | |
| SCHEMBL13567769 | 0.99 | UGCG (1.00) | UGCGMEN1KMT2ATP53CYP3A4 | |
| SCHEMBL7677086 | 0.99 | UGCG (1.00) | UGCGMEN1KMT2ATP53CYP3A4 | |
| SCHEMBL31275968 | 0.99 | UGCG (1.00) | UGCGMEN1KMT2ATP53CYP3A4 | |
| SCHEMBL13398086 | 0.99 | UGCG (1.00) | UGCGMEN1KMT2ATP53CYP3A4 | |
| SCHEMBL23845861 | 0.99 | UGCG (1.00) | UGCGMEN1KMT2ATP53CYP3A4 | |
| SCHEMBL7101172 | 0.99 | UGCG (1.00) | UGCGMEN1KMT2ATP53CYP3A4 | |
| SCHEMBL295611 | 0.99 | UGCG (1.00) | UGCGMEN1KMT2ATP53CYP3A4 | |
| SCHEMBL12087892 | 0.99 | UGCG (1.00) | UGCGMEN1KMT2ATP53CYP3A4 | |
| SCHEMBL13567767 | 0.98 | UGCG (0.98) | UGCGMEN1KMT2ATP53CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090202439-A1 | Methods for treatment of angiogenesis | THE JOHNS HOPKINS UNIVERSITY (US) | 2009-08-13 | — | — | US | claimed |
| EP-1799258-A4 | METHODS FOR TREATMENT OF ANGIOGENESIS | UNIV JOHNS HOPKINS (US) | 2009-07-22 | — | — | EP | claimed |
| EP-0996433-A4 | METHODS FOR TREATMENT OF CONDITIONS ASSOCIATED WITH LACTOSYLCERAMIDE | UNIV JOHNS HOPKINS (US) | 2009-05-27 | — | — | EP | claimed |
| EP-1825853-A2 | Methods for treating conditions modulated by lactosyceramide | Johns Hopkins University (US) | 2007-08-29 | — | — | EP | claimed |
| EP-1799258-A2 | METHODS FOR TREATMENT OF ANGIOGENESIS | THE JOHNS-HOPKINS UNIVERSITY (US) | 2007-06-27 | — | — | EP | claimed |
| EP-1098642-B1 | DIAMINO-PROPANOL-COMPOUNDS FOR TREATING ISCHEMIA | UNIV JOHNS HOPKINS (US) | 2007-04-04 | — | — | EP | claimed |
| WO-2006023827-A2 | METHODS FOR TREATMENT OF ANGIOGENESIS | THE JOHNS HOPKINS UNIVERSITY (US) | 2006-03-02 | — | — | WO | claimed |
| EP-1098642-A4 | METHODS FOR TREATING CONDITIONS MODULATED BY LACTOSYLCERAMIDE | UNIV JOHNS HOPKINS (US) | 2004-08-18 | — | — | EP | claimed |
| US-6511979-B1 | Administering a therapeutically effective amount of a levorotatory GalT-2 galactosyltransferase enhancing compound such as 1-phenyl-2-decanoylamino-3-morpholino-1-propanol; wherein the condition is a bacterial infection or | JOHNS HOPKINS UNIVERSITY | 2003-01-28 | — | — | US | claimed |
| JP-2002521435-A | — | — | 2002-07-16 | — | — | JP | claimed |
| EP-1098642-A1 | METHODS FOR TREATING CONDITIONS MODULATED BY LACTOSYLCERAMIDE | THE JOHNS HOPKINS UNIVERSITY (US) | 2001-05-16 | — | — | EP | claimed |
| EP-0996433-A1 | METHODS FOR TREATMENT OF CONDITIONS ASSOCIATED WITH LACTOSYLCERAMIDE | THE JOHNS HOPKINS UNIVERSITY (US) | 2000-05-03 | — | — | EP | claimed |
| WO-2000006145-A1 | METHODS FOR TREATING CONDITIONS MODULATED BY LACTOSYLCERAMIDE | JOHNS HOPKINS UNIVERSITY (US) | 2000-02-10 | — | — | WO | claimed |
| US-20090202439-A1 | Methods for treatment of angiogenesis | THE JOHNS HOPKINS UNIVERSITY (US) | 2009-08-13 | — | — | US | disclosed |
| EP-1799258-A4 | METHODS FOR TREATMENT OF ANGIOGENESIS | UNIV JOHNS HOPKINS (US) | 2009-07-22 | — | — | EP | disclosed |
| EP-0996433-A4 | METHODS FOR TREATMENT OF CONDITIONS ASSOCIATED WITH LACTOSYLCERAMIDE | UNIV JOHNS HOPKINS (US) | 2009-05-27 | — | — | EP | disclosed |
| US-6228889-B1 | Methods for treatment of conditions associated with lactosylceramide | JOHNS HOPKINS UNIVERSITY | 2001-05-08 | — | — | US | disclosed |
| EP-0996433-A1 | METHODS FOR TREATMENT OF CONDITIONS ASSOCIATED WITH LACTOSYLCERAMIDE | THE JOHNS HOPKINS UNIVERSITY (US) | 2000-05-03 | — | — | EP | disclosed |
| US-5972928-A | ADMINISTERING AN ANTIGROWTH AGENT | JOHNS HOPKINS UNIVERSITY (US) | 1999-10-26 | — | — | US | disclosed |
| WO-1998052553-A1 | METHODS FOR TREATMENT OF CONDITIONS ASSOCIATED WITH LACTOSYLCERAMIDE | JOHNS HOPKINS UNIVERSITY (US) | 1998-11-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090202439-A1 | Methods for treatment of angiogenesis | B4GALT1, FLT1, FLT4 | UGCG 5/4885MEN1 4477/4885KMT2A 1679/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.